Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

  1. Mok, T.S.
  2. Cheng, Y.
  3. Zhou, X.
  4. Lee, K.H.
  5. Nakagawa, K.
  6. Niho, S.
  7. Chawla, A.
  8. Rosell, R.
  9. Corral, J.
  10. Migliorino, M.R.
  11. Pluzanski, A.
  12. Noonan, K.
  13. Tang, Y.
  14. Pastel, M.
  15. Wilner, K.D.
  16. Wu, Y.-L.
Zeitschrift:
Drugs

ISSN: 1179-1950,  0012-6667

Datum der Publikation: 2021

Ausgabe: 81

Nummer: 2

Seiten: 257-266

Art: Artikel

DOI: 10.1007/S40265-020-01441-6 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus